These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 39122474)

  • 1. Socioeconomic burden of cystic fibrosis in Canada.
    Laflamme OD; Johnson N; Steele K; Chavez L; Cheng SY; Rabin HR; Cheema ZM; Mamic E; Gomez LC; Leong J; Quon BS; Sadatsafavi M; Stephenson AL; Wranik WD; Eckford PDW; Wallenburg J; Bowerman C; Stanojevic S
    BMJ Open Respir Res; 2024 Aug; 11(1):. PubMed ID: 39122474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical, economic, and societal burden of cystic fibrosis and the impact of the CFTR modulator, lumacaftor/ivacaftor: an assessment using linked registry data in Sweden.
    Lindblad A; Monestrol I; Gilljam M; Krantz C; McGarry LJ; Banefelt J; Aldvén M
    J Med Econ; 2024; 27(1):897-906. PubMed ID: 38939921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measuring the burden of cystic fibrosis: A scoping review.
    Cheema ZM; Gomez LC; Johnson N; Laflamme OD; Rabin HR; Steele K; Wallenburg J; Leong J; Cheng SY; Quon BS; Stephenson AL; Wranik WD; Sadatsafavi M; Stanojevic S
    J Cyst Fibros; 2024 Sep; 23(5):823-830. PubMed ID: 38044160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Impact of Inflammatory Bowel Disease in Canada 2018: Indirect Costs of IBD Care.
    Kuenzig ME; Lee L; El-Matary W; Weizman AV; Benchimol EI; Kaplan GG; Nguyen GC; Bernstein CN; Bitton A; Lee K; Cooke-Lauder J; Murthy SK
    J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S34-S41. PubMed ID: 31294383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Social and economic costs and health-related quality of life in non-institutionalised patients with cystic fibrosis in the United Kingdom.
    Angelis A; Kanavos P; López-Bastida J; Linertová R; Nicod E; Serrano-Aguilar P;
    BMC Health Serv Res; 2015 Sep; 15():428. PubMed ID: 26416027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost of illness of cystic fibrosis in Germany: results from a large cystic fibrosis centre.
    Heimeshoff M; Hollmeyer H; Schreyögg J; Tiemann O; Staab D
    Pharmacoeconomics; 2012 Sep; 30(9):763-77. PubMed ID: 22690685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Social/economic costs and health-related quality of life in patients with cystic fibrosis in Europe.
    Chevreul K; Michel M; Brigham KB; López-Bastida J; Linertová R; Oliva-Moreno J; Serrano-Aguilar P; Posada-de-la-Paz M; Taruscio D; Schieppati A; Iskrov G; Péntek M; von der Schulenburg JM; Kanavos P; Persson U; Fattore G;
    Eur J Health Econ; 2016 Apr; 17 Suppl 1():7-18. PubMed ID: 27059622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimating Direct Cost of Cystic Fibrosis Care Using Irish Registry Healthcare Resource Utilisation Data, 2008-2012.
    Jackson AD; Jackson AL; Fletcher G; Doyle G; Harrington M; Zhou S; Cullinane F; Gallagher C; McKone E
    Pharmacoeconomics; 2017 Oct; 35(10):1087-1101. PubMed ID: 28699086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temporal trends in healthcare resource use and associated costs of patients with cystic fibrosis.
    Durieu I; Dalon F; Reynaud Q; Lemonnier L; Dehillotte C; Bérard M; Walther D; Viprey M; Van Ganse E; Belhassen M
    J Cyst Fibros; 2022 Jan; 21(1):88-95. PubMed ID: 33865726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-of-illness analysis and regression modeling in cystic fibrosis: a retrospective prevalence-based study.
    Mlčoch T; Klimeš J; Fila L; Vávrová V; Skalická V; Turnovec M; Krulišová V; Jirčíková J; Zemková D; Dědečková KV; Bílková A; Frühaufová V; Homola L; Friedmannová Z; Drnek R; Dřevínek P; Doležal T; Macek M
    Eur J Health Econ; 2017 Jan; 18(1):73-82. PubMed ID: 26743971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Economic Burden of Cystic Fibrosis in Germany from a Payer Perspective.
    Frey S; Stargardt T; Schneider U; Schreyögg J
    Pharmacoeconomics; 2019 Aug; 37(8):1029-1039. PubMed ID: 30949989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Costs of treatment of adult patients with cystic fibrosis in Poland and internationally.
    Kopciuch D; Zaprutko T; Paczkowska A; Nowakowska E
    Public Health; 2017 Jul; 148():49-55. PubMed ID: 28404533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Socioeconomic costs and health-related quality of life in juvenile idiopathic arthritis: a cost-of-illness study in the United Kingdom.
    Angelis A; Kanavos P; López-Bastida J; Linertová R; Serrano-Aguilar P;
    BMC Musculoskelet Disord; 2016 Aug; 17():321. PubMed ID: 27484740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Italian Cystic Fibrosis Register - Report 2010].
    Amato A; Ferrigno L; Salvatore M; Toccaceli V;
    Epidemiol Prev; 2016; 40(2 Suppl 2):1-47. PubMed ID: 27291389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct healthcare costs in the first 2 years of life: A comparison of screened and clinically diagnosed children with cystic fibrosis - The Irish comparative outcomes study of CF (ICOS).
    Somerville R; Fitzgerald C; Segurado R; Kapur K; George S; Bhardwaj N; Linnane B; O'Ceilleachair A; Staines A; Fitzpatrick P
    J Cyst Fibros; 2024 Sep; 23(5):896-902. PubMed ID: 38964978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cystic fibrosis: cost of illness and considerations for the economic evaluation of potential therapies.
    Krauth C; Jalilvand N; Welte T; Busse R
    Pharmacoeconomics; 2003; 21(14):1001-24. PubMed ID: 13129414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Italian Cystic Fibrosis Registry (ICFR). Report 2021-2022].
    Campagna G; Amato A; Majo F; Ferrari G; Quattrucci S; Padoan R; Floridia G; Salvatore D; Carnovale V; Puppo Fornaro G; Taruscio D; Salvatore M;
    Epidemiol Prev; 2024; 48(2 Suppl 2):1-41. PubMed ID: 38742380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Global disparities in cystic fibrosis outcomes prior to CFTR modulators: A CF registries cohort study in South Africa and Canada.
    Zampoli M; Sykes J; Verstraete J; Cheng SY; Morrow B; Pepper MS; Stewart C; Zar HJ; Stephenson AL
    J Cyst Fibros; 2024 Mar; 23(2):334-340. PubMed ID: 37704465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Up-to-date and projected estimates of survival for people with cystic fibrosis using baseline characteristics: A longitudinal study using UK patient registry data.
    Keogh RH; Szczesniak R; Taylor-Robinson D; Bilton D
    J Cyst Fibros; 2018 Mar; 17(2):218-227. PubMed ID: 29311001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Healthcare expenditures for privately insured US patients with cystic fibrosis, 2010-2016.
    Grosse SD; Do TQN; Vu M; Feng LB; Berry JG; Sawicki GS
    Pediatr Pulmonol; 2018 Dec; 53(12):1611-1618. PubMed ID: 30381911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.